- Case report
- Open Access
- Open Peer Review
An uncommon presentation and course of metastatic malignant melanoma: a case report
© Dalhaug et al; licensee BioMed Central Ltd. 2007
- Received: 19 September 2007
- Accepted: 26 November 2007
- Published: 26 November 2007
Most patients with brain metastases from malignant melanoma are diagnosed after treatment for known extracranial metastases and have a poor outcome despite various local and systemic therapeutic approaches. Here we discuss an unusual case where a 45-year old patient presented with a brain metastasis as the first symptom of disease and where the presumed primary lesion later was found in the gastro-intestinal tract. Treatment consisted of sequential surgical removal of a total of 4 tumor sites (2 extracranially), whole-brain radiotherapy and two radiosurgery procedures within 13 months. Following her last treatment, the patient has now been in remission for 20 months. This case illustrates that some patients with multi-organ melanoma manifestations may benefit from the repeated use of effective local therapeutic approaches and may experience a quite favourable prognosis.
- Brain Metastasis
- Karnofsky Performance Status
- Adrenal Mass
- Extracranial Metastasis
Malignant melanoma is next to lung cancer, the most frequent cause of brain metastasis . These metastases usually develop late in the course of the disease. Only 7% of patients had brain metastases disclosed at the time of initial diagnosis . It is uncommon that melanoma patients with brain metastases continue to have an occult primary tumor after initial thorough work-up and staging. In the study by Fife and coworkers, the figure was 14% . The course of disease is typically characterised by rapid extracranial progression and short overall survival time despite various local and systemic treatment approaches. Here the authors discuss an unusual case where a patient presented with a brain metastasis as the first symptom of disease, a presumed primary in the gastro-intestinal tract and favourable survival and disease-control in the absence of any systemic therapy.
After a symptom-free interval, routine MR evaluation in November 2005 disclosed tumor progression of the temporal lesion and a second gamma-knife procedure was performed. Since then, the patient returned to repeated follow-up examinations including MR and CT scans. The last one was performed in July 2007. As shown in Figure 1, there is a stable residual abnormality with contrast-enhancement in the temporal lobe after repeated gamma-knife treatments, possibly representing treatment effects rather than active tumor. No other potential signs of disease were detectable. The patient has a Karnofsky performance status (KPS) of 80% resulting from slight concentration and endurance problems. She has never received systemic treatment during the whole course of disease, although she initially was interested in participation in a clinical trial. However, all trials that were open in Norway at that time did explicitly exclude patients with brain metastases.
Neurological symptoms as the first sign of malignant melanoma are relatively uncommon, as is the inability to identify the primary tumor in patients with brain metastases from this disease . The patient described here, had an adrenal mass that was detected shortly after diagnosis of the first brain lesion. Although primary adrenal melanoma has occasionally been described, the vast majority of adrenal lesions represent distant metastases . It appears more likely that the primary tumor was located in the vermiform appendix, where it became symptomatic approximately five months after diagnosis of the disease. Primary melanoma arising from the mucosal epithelium of the gastrointestinal tract is also a rare entity and the differentiation between metastatic and primary tumors is very difficult . However, no other lesion that might represent the primary was detectable in this patient.
Radiotherapy plays an important role in palliative treatment in this setting. Patients with a single brain metastasis managed with surgical resection plus WBRT have a 2-year survival rate of 20–25% . Besides resection, prognostic factors included younger age, long disease-free interval and no concurrent extracranial metastases. In our patient, both salvage surgery and RS had to be performed relatively soon after WBRT. RS-reirradiation for local progression finally resulted in long-term control. It has recently been increasingly adopted that re-irradiation in primary and metastatic brain tumors might represent a valuable therapeutic option without unacceptable toxicity risk . RS for melanoma brain metastases was reported to result in 1-year local control in 49% and overall survival in 25% of the patients, with survival being dependent on the score index for radiosurgery (SIR) . The present patient belonged to the favourable SIR group (age ≤50 years, KPS >70%, no evidence of systemic disease at the time of RS, limited number of brain lesions and largest RS-treated lesion <13 ccm). The gamma-knife group from Pittsburgh described their results in 244 patients with melanoma brain metastases . Median survival was 8 months and brain disease the cause of death in 40.5% of the patients. Those with controlled systemic disease, single brain metastasis and KPS 90–100% had better survival. A smaller recent series reported a median survival of 11 months and 2-year survival rate of 18% . These authors emphasize that surgery or multiple RS procedures were associated with prolonged survival.
Throughout the melanoma literature, long-term survival after complete resection of metastatic disease has been reported repeatedly [9, 10]. Despite new drugs, local responses after systemic treatment are infrequent, e.g., 10% in a recent report . However, local response is significantly associated with longer survival . Based on these facts and illustrated through the case discussed here, effective local therapeutic measures including, e.g., surgical resection and high-dose stereotactic radiotherapy, should be considered in patients with favourable prognostic factors and absence of rapid and synchronous multi-organ spread.
This case illustrates that patients with multi-organ melanoma manifestations may benefit from the repeated use of effective local therapeutic approaches and may experience a quite favourable prognosis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004, 22: 2865-2872. 10.1200/JCO.2004.12.149.View ArticlePubMedGoogle Scholar
- Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, McCarthy WH, Thompson JF: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004, 22: 1293-1300. 10.1200/JCO.2004.08.140.View ArticlePubMedGoogle Scholar
- Rajaratnam A, Waugh J: Adrenal metastases of malignant melanoma: characteristic computed tomography appearances. Australas Radiol. 2005, 49: 325-329. 10.1111/j.1440-1673.2005.01440.x.View ArticlePubMedGoogle Scholar
- Schuchter LM, Green R, Fraker D: Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol. 2000, 12: 181-185. 10.1097/00001622-200003000-00014.View ArticlePubMedGoogle Scholar
- Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D: Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol. 2005, 181: 768-773. 10.1007/s00066-005-1415-6.View ArticlePubMedGoogle Scholar
- Selek U, Chang EL, Hassenbusch SJ, Shiu AS, Lang FF, Allen P, Weinberg J, Sawaya R, Maor MH: Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004, 59: 1097-1106. 10.1016/j.ijrobp.2003.12.037.View ArticlePubMedGoogle Scholar
- Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD: Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007, 60: 471-481.PubMedGoogle Scholar
- Samlowski WE, Watson GA, Wang M, Rao G, Klimo P, Boucher K, Shrieve DC, Jensen RL: Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery. Cancer. 2007, 109: 1855-1862. 10.1002/cncr.22605.View ArticlePubMedGoogle Scholar
- Wong SL, Coit DG: Role of surgery in patients with stage IV melanoma. Curr Opin Oncol. 2004, 16: 155-160. 10.1097/00001622-200403000-00013.View ArticlePubMedGoogle Scholar
- Young SE, Martinez SR, Essner R: The role of surgery in treatment of stage IV melanoma. J Surg Oncol. 2006, 94: 344-351. 10.1002/jso.20303.View ArticlePubMedGoogle Scholar
- Richtig E, Ludwig R, Kerl H, Smolle J: Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. Br J Dermatol. 2005, 153: 925-931. 10.1111/j.1365-2133.2005.06796.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.